Verily and iRhythm To Redefine AFib Diagnosis with Data Analytics and AI

Alphabet's Verily Life Sciences and iRhythm Technologies are bringing together data analytics and artificial intelligence to improve the condition of Atrial Fibrillation (AFib) patients. "We expect … that [in] a two-year-time frame that we will be showing the product from this collaboration," Karti, told MD DI. San Francisco-based iRhythm is a company known for operating in the intersection of cardiology and AI. The firm has developed Zio Patch XT, a wearable technology that can monitor heart rate activity for up to 14 days. Karti said the collaboration will focus on asymptomatic patients that potentially have AFib. "This [collaboration] is aimed at a very significant patient population," he said.